RE-BVS – Piemonte Repository

Sfoglia per AUTORE
PELLA N
Collezione ASL Biella

Items : 10

Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. in Journal of gastrointestinal cancer / J Gastrointest Cancer. 2022 Jun;53(2):289-298. doi: 10.1007/s12029-021-00596-z. Epub 2021 Feb 5.

2022
ASL Biella
AO Ordine Mauriziano
AOU Città della Salute di Torino

Casadei-Gardini A; Cascinu S; Jeong JH; Aprile G; Orsi G; Vasile E; de Braud F; Di Maio M; Nichetti F; Pella N; De Lorenzo S; Fenocchio E; Lai E; Cho H; Aglietta M; Vivaldi C; Palloni A; Santini D; Casagrande M; Faloppi L; Silvestris N; Caputo F; Filippi R; Niger M; Yoo C; Scartozzi M; Brandi G; Fornaro L; Rovesti G; et alii...

Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy. in Journal of chemotherapy (Florence, Italy) / J Chemother. 2022 Dec;34(8):543-549. doi: 10.1080/1120009X.2022.2036557. Epub 2022 Feb 14.

2022
ASL Biella
AO Ordine Mauriziano
AOU Città della Salute di Torino

Cucchetti A; Ratti F; Aldrighetti L; Cascinu S; Burgio V; Faloppi L; Sperti E; Pellino A; Scartozzi M; Satolli MA; Salani F; Fenocchio E; Vivaldi C; Aprile G; Frega G; Aglietta M; Masi G; Filippi R; Galizia E; Palloni A; Santini D; Lonardi S; Lai E; Montagnani F; Pella N; Silvestris N; Fornaro L; Brandi G; Leone F; et alii...

Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. in Scientific reports / Sci Rep. 2020 Jan 31;10(1):1918. doi: 10.1038/s41598-020-58486-6.

2020
ASL Biella

Ruzzo A; Graziano F; Galli F; Galli F; Rulli E; Lonardi S; Ronzoni M; Massidda B; Zagonel V; Pella N; Mucciarini C; Labianca R; Ionta MT; Bagaloni I; Veltri E; Sozzi P; Barni S; Ricci V; Foltran L; Nicolini M; Biondi E; Bramati A; Turci D; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Frontini L; Magnani M; et alii...

Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial in Therapeutic Advances in Medical Oncology

2020
ASL Biella

Barni S; Rosati G; Lonardi S; Pella N; Banzi M; Zampino MG; Dotti KF; Rimassa L; Marchetti P; Maiello E; Artioli F; Ferrari D; Labianca R; Bidoli P; Zaniboni A; Sobrero A; Iaffaioli V; De Placido S; Frassineti GL; Ciarlo A; Buonadonna A; Silvestris N; Piazza E; Pavesi L; Moroni M; Clerico M; Aglietta M; Giordani P; Galli F; et alii...

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. in Scientific reports / Sci Rep. 2019 Aug 8;9(1):11527. doi: 10.1038/s41598-019-47627-1.

2019
ASL Biella

Predicting HER2 status in esophagogastric cancer: Development and validation of an easy-to-use nomogram in Annals of Oncology

2018
ASL Biella

Fornaro L; Parnofiello A; Ugolini C; Cardarelli N; De Maglio G; Pecora I; Crivelli F; Catanese S; Cardellino G; Musettini G; Pella N; Pasquini G; Pizzolitto S; Salani F; Clerico M; Fontanini G; Fasola G; Maurizio D; Vivaldi C; Montagnani F;

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. in British journal of cancer / Br J Cancer. 2017 Oct 24;117(9):1269-1277. doi: 10.1038/bjc.2017.289. Epub 2017 Aug 24.

2017
ASL Biella

Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: A pharmacogenetic ancillary study to TOSCA trial in Annals of Oncology

2017
ASL Biella

Ruzzo A; Galli F; Galli F; Rulli E; Lonardi S; Zagonel V; Ronzoni M; Ionta MT; Pella N; Mucciarini C; Labianca R; Veltri E; Sozzi P; Barni S; Nicolini M; Biondi E; Bramati A; Turci D; Buscaglia M; Magnani M; Graziano F;

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL (ColorEctalvastiNTRiAlLdh) and SENTRAL (Serum angiogenesis-cENTRAL) analysis in Journal of Clinical Oncology

2016
ASL Biella

Scartozzi M; Giampieri R; Daniele B; Ferrari D; Lonardi S; Zaniboni A; Cavanna L; Rosati G; Pella N; Zampino MG; Sozzi P; Casula L; Cozzi L; Germano D; Puzzoni M; Loretelli C; Zagonel V; Labianca R; Frontini L; Cascinu S;

Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. in Scientific reports / Sci Rep. 2014 Nov 5;4:6828. doi: 10.1038/srep06828.

2014
ASL Biella

Ruzzo A; Graziano F; Galli F; Giacomini E; Floriani I; Galli F; Rulli E; Lonardi S; Ronzoni M; Massidda B; Zagonel V; Pella N; Mucciarini C; Labianca R; Ionta MT; Veltri E; Sozzi P; Barni S; Ricci V; Foltran L; Nicolini M; Biondi E; Bramati A; Turci D; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Frontini L; et alii...